S.3 Ep. 4 Highlights from the 2020 ASCO Annual Meeting CGA-IGC Podcast Series
-
- Education
This episode is hosted by Dr. Leah Biller and features Dr. Zsofia Stadler, a medical oncologist at Memorial Sloan Kettering Cancer Center and CGA council member, and Dr. Michael Hall, a medical oncologist at Fox Chase Cancer Center and CGA past president. They discuss data from Abstract 1500 (https://meetinglibrary.asco.org/record/185963/abstract), which reports on targeted therapy based on germline analysis of tumor-normal sequencing in a pan-cancer population, as well as data from the plenary presentation about the clinical trial KEYNOTE-177 (https://meetinglibrary.asco.org/record/186928/abstract), a study of pembrolizumab versus standard therapy for treatment of MSI-H metastatic colorectal cancer.
This episode was recorded on August 28, 2020 and reflects expert opinion at the time of the recording.
This episode is hosted by Dr. Leah Biller and features Dr. Zsofia Stadler, a medical oncologist at Memorial Sloan Kettering Cancer Center and CGA council member, and Dr. Michael Hall, a medical oncologist at Fox Chase Cancer Center and CGA past president. They discuss data from Abstract 1500 (https://meetinglibrary.asco.org/record/185963/abstract), which reports on targeted therapy based on germline analysis of tumor-normal sequencing in a pan-cancer population, as well as data from the plenary presentation about the clinical trial KEYNOTE-177 (https://meetinglibrary.asco.org/record/186928/abstract), a study of pembrolizumab versus standard therapy for treatment of MSI-H metastatic colorectal cancer.
This episode was recorded on August 28, 2020 and reflects expert opinion at the time of the recording.
28 min